LianBio Collaboration Agreements
6 Contracts & Agreements
- License and Collaboration Agreement, dated as of February 28, 2023, by and between LianBio Development (HK) Limited and NImmune Biopharma, Inc (Filed With SEC on March 28, 2023)
- First Amendment to License and Collaboration Agreement, dated as of February 28, 2023 by and between LianBio Respiratory Limited and Landos BioPharma, Inc (Filed With SEC on March 28, 2023)
- Amendment No. 1 to License and Collaboration Agreement, dated as of September 26, 2022, by and among LianBio Inflammatory Limited and Lyra Therapeutics, Inc (Filed With SEC on November 10, 2022)
- License and Collaboration Agreement, dated May 31, 2021, by and among LianBio Inflammatory Limited, LianBio and Lyra Therapeutics, Inc (Filed With SEC on October 1, 2021)
- License and Collaboration Agreement, dated May 14, 2021, by and between LianBio Respiratory Limited and Landos BioPharma, Inc (Filed With SEC on October 1, 2021)
- Strategic Collaboration Agreement, dated November 17, 2020, by and between LianBio and Pfizer Inc (Filed With SEC on October 1, 2021)